Overview
Background
Dr Brett Hughes graduated from the University of NSW with a Bachelor of Medical Science and Bachelor of Medicine and Surgery in 1997. He completed his postgraduate training in Canberra and Brisbane and was admitted as a Fellow of the Australian College of Physicians as a Specialist Medical Oncologist in 2005.
Dr Hughes is currently a Senior Staff Specialist Medical Oncologist at the RBWH and TPCH. He is also an Associate Professor at the University of Queensland since 2015. As the previous Clinical Director of Oncology (201-2017) and current Cancer Care Services Research lead at TPCH, Dr Hughes has established both an independent TPCH Oncology unit and continuing TPCH’s reputation as a lung cancer research centre of excellence.
Dr Hughes is an active senior member of the Thoracic Oncology Group Australasia (TOGA) and the Trans Tasman Radiation Oncology Group (TROG). He is also heavily involved in many pivotal multicentre trials of cancer therapy at both TPCH and RBWH with his principal research interests in Lung cancer, Head & Neck cancer, Mesothelioma, cutaneous SCC and Thyroid cancer. He has published over 100 peer review papers. Dr Hughes is also involved in undergraduate and post graduate teaching in his fields of research interest.
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Fields of research
Works
Search Professor Brett Hughes’s works on UQ eSpace
2019
Journal Article
The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer
Turner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Hughes, Brett G. M., McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Paviour, Alana, Skerman, Helen, Batstone, Martin and Mackenzie, Lisa (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer, 27 (12), 4627-4637. doi: 10.1007/s00520-019-04748-7
2019
Conference Publication
Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)
Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129
2019
Journal Article
Patterns of care for stage III non–small cell lung cancer in Australia
Parente, Phillip, Chan, Bryan A., Hughes, Brett G. M., Jasas, Kevin, Joshi, Rohit, Kao, Steven, Hegi-Johnson, Fiona, Hui, Rina, McLaughlin-Barrett, Sara, Nordman, Ina and Stone, Emily (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 15 (3), 93-100. doi: 10.1111/ajco.13140
2019
Conference Publication
Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging
Senko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology.
2019
Conference Publication
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Baste, Neus, Neupane, Prakash C., Bratland, Ase, Fuereder, Thorsten, Hughes, Brett Gordon Maxwell, Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Zhang, Yayan, Jin, Fan, Gumuscu, Burak and Burtness, Barbara (2019). Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6000
2019
Conference Publication
KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)
Grob, Jean Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica Ruth, Grange, Florent, Meyer, Nicolas, Piulats, Josep M., Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett Gordon Maxwell (2019). KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.TPS9598
2019
Conference Publication
Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up
Guminski, Alexander David, Lim, Annette May Ling, Khushalani, Nikhil I., Schmults, Chrysalyne D., Hernandez-Aya, Leonel Fernando, Modi, Badri, Dunn, Lara, Hughes, Brett Gordon Maxwell, Chang, Anne Lynn S., Hauschild, Axel, Migden, Michael Robert, Gutzmer, Ralf, Alam, Murad, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2019). Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 Jun 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.9526
2019
Conference Publication
Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC)
Wirth, Lori J., Leboulleux, Sophie, Kiyota, Naomi, Tahara, Makoto, Muro, Kei, Ahn, Myung-Ju, Ando, Yuichi, Taylor, Matthew H., Takahashi, Shunji, Kim, Sung-Bae, Misir, Soamnauth, Dutcus, Corina E., Xie, Ran, Joshi, Prashant Ramesh, Hughes, Brett Gordon Maxwell, Aller, Javier, Krzyzanowska, Monika K. and Capdevila, Jaume (2019). Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2019.37.15_suppl.6081
2018
Journal Article
Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger and John, Thomas (2018). Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13 (11), 1784-1791. doi: 10.1016/j.jtho.2018.08.007
2018
Conference Publication
Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer
Itchins, M., Alexander, M., John, T., Kao, S., Hughes, B., Hayes, S., Howel, V., Harvie, R., Clarke, S., Millward, M. and Pavlakis, N. (2018). Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jtho.2018.08.1104
2018
Journal Article
Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Tran, Q., Schimdt, A., Lwin, Z. and Hughes, B. G. M. (2018). Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. Annals of Oncology, 29, viii756. doi: 10.1093/annonc/mdy424.088
2018
Conference Publication
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., De Castro, G., Psyrri, A., Rotllan, N. Baste, Neupane, P. C., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. Wan, Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS.
2018
Conference Publication
Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P. C., Bratland,, Fuereder, T., Hughes, B. G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Roy, A., Cheng, J., Jin, F. and Rischin, D. (2018). Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.045
2018
Journal Article
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., Li, J., Mathias, M., Booth, J., Mohan, K., Stankevich, E., Babiker, H. M., Brana, I., Gil-Martin, M., Homsi, J. ... Fury, M. G. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine, 379 (4), 341-351. doi: 10.1056/NEJMoa1805131
2018
Journal Article
Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns
Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Burns, Clare L., Yeo, Shu Qi, Pelecanos, Anita, Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer, 27 (2), 1-9. doi: 10.1007/s00520-018-4352-5
2018
Journal Article
CXCR4 and PD-1 expression in head and neck cancer with perineural spread
Barnett, Catherine M., Sommerville, Ryan S., Lin, Charles, Ratnayake, Gishan, Hughes, Brett and Taheri, Touraj (2018). CXCR4 and PD-1 expression in head and neck cancer with perineural spread. Journal of Neurological Surgery, Part B: Skull Base, 80 (01), 018-022. doi: 10.1055/s-0038-1660846
2018
Journal Article
Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns
Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Pelecanos, Anita, Burns, Clare L., Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns. Head & Neck, 40 (9), 1955-1966. doi: 10.1002/hed.25182
2018
Journal Article
Osimertinib in Untreated <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer
Soria, J. -C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. -C., Gray, J. E., Lee, S. -M., Hodge, R., Marotti, M., Rukazenkov, Y., Ramalingam, S. S., Boyer, Michael, Lee, Chee, Hughes, Brett, O'Byrne, Kenneth, Briggs, Peter ... Nguyen, Nhung (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378 (2), 113-125. doi: 10.1056/NEJMoa1713137
2018
Conference Publication
Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC
Socinski, M. A., Rittmeyer, A., Shapovalov, D., Orlandi, F., McCleod, M., Soo, R. A., Palmero, R., Kozuki, T., Migliorino, M. R., Koynov, K. D., Berard, H., Hughes, B. G. M., Yu, W., Graupner, V., Sun, S. W., Kowanetz, M., Hoang, T., Lin, W. and Jotte, R. M. (2018). Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC. 43rd ESMO Congress, Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy424.077
2018
Conference Publication
BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC
Kulkarni, S., Laurie, S., Goss, G., Perrone, F., Hughes, B., Pavlakis, N., Stockler, M., Blais, A., Zibdawi, L., Vera-Badillo, F. and Leighl, N. (2018). BR-34-randomized trial of durvalumab and tremelimumab +/- platinum chemotherapy in patients with metastatic squamous or non-squamous NSCLC. IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 23-26 September 2018. New York, NY USA: Elsevier. doi: 10.1016/j.jtho.2018.08.608
Supervision
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
The changing face of head and neck cancer: addressing and advancing best-practice nutritional care to improve outcomes for patients with human papillomavirus-associated disease
Associate Advisor
-
Doctor Philosophy
Developing predictive biomarkers for immunotherapy using deep spatial profiling
Associate Advisor
Other advisors: Associate Professor Arutha Kulasinghe
Completed supervision
-
2025
Doctor Philosophy
The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy
Associate Advisor
Other advisors: Dr Quan Nguyen, Associate Professor Arutha Kulasinghe
Media
Enquiries
For media enquiries about Associate Professor Brett Hughes's areas of expertise, story ideas and help finding experts, contact our Media team: